Abstract
Background: Clinical remission is an emerging, ambitious treatment goal in severe asthma, characterized by sustained absence of symptoms and exacerbations, and normalization of lung function while off or on minimal treatment. Easily accessible predictors are needed to guide therapy. Serum biomarkers represent promising candidates.
Objective: To systematically review and synthesize the evidence on the association between serum biomarker levels and the achievement of clinical remission in patients with severe asthma.
Methods: We searched PubMed, Embase, and Cochrane Central Register of Controlled Trials from inception to October 2025 for observational studies and clinical trials that reported on serum biomarkers and a predefined outcome of clinical remission in severe asthma. Study quality was assessed using the Newcastle-Ottawa Scale.
Results: 18 studies (n=4,250 patients) were included. Key biomarkers studied were serum eosinophil count (sEOS), periostin, IgE, and specific cytokines. Higher baseline sEOS was consistently associated with a greater likelihood of achieving remission on biologic therapy (OR 2.1, 95% CI 1.5-2.9). A baseline sEOS ≥150 cells/μL was the most robust predictor . Serum periostin showed a modest positive association (OR 1.6, 95% CI 1.1-2.3), while total IgE was not predictive (OR 1.0, 95% CI 0.8-1.3). Emerging biomarkers like IL-5 and IL-13 receptor levels showed promise but evidence was limited.
Conclusion: Current evidence supports serum eosinophil count as a significant predictor of clinical remission in severe asthma, particularly for patients initiating specific biologic therapies. Serum periostin may have a secondary role. Standardized definitions of remission and prospective validation are required for clinical implementation.
Keywords
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.